To read the full story, subscribe or sign in.

Neurophet nets ₩20B from financing, slates Kosdaq IPO for 2024

Nov. 13, 2023

Neurophet Inc. pulled in ₩20 billion (US$15.1 million) in its series C funding round, helping roll out its AI-software suite for neurodegenerative diseases worldwide and prep its IPO on the Kosdaq which is scheduled to take place sometime in 2024.

Financings Medical technology Software Imaging Artificial intelligence Neurology/psychiatric Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Science

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Asia

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Capital remains selective in ‘barbell’ biotech market

BioWorld Asia

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...